

Research article

Open Access

## Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an *in vitro* study

Crystel Ogier<sup>1</sup>, Rita Creidy<sup>1</sup>, José Boucraut<sup>1</sup>, Paul D Soloway<sup>2</sup>,  
Michel Khrestchatisky<sup>1</sup> and Santiago Rivera\*<sup>1</sup>

Address: <sup>1</sup>Neurobiologie des Interactions Cellulaires et Neurophysiopathologie (NICN), CNRS UMR 6184, Université de la Méditerranée, Faculté de Médecine de Marseille, IFR Jean Roche, Bd. Pierre Dramard, 13916, Marseille cedex 20, France and <sup>2</sup>Division of Nutritional Sciences College of Agriculture and Life Sciences, Cornell University 108 Savage Hall Ithaca, NY 14853-6301 USA

Email: Crystel Ogier - ogier.c@jean-roche.univ-mrs.fr; Rita Creidy - creidy.r@jean-roche.univ-mrs.fr; José Boucraut - jose.boucraut@medecine.univ-mrs.fr; Paul D Soloway - pds28@cornell.edu; Michel Khrestchatisky - khrestchatisky.m@jean-roche.univ-mrs.fr; Santiago Rivera\* - rivera.s@jean-roche.univ-mrs.fr

\* Corresponding author

Published: 29 November 2005

Received: 24 June 2005

BMC Neuroscience 2005, 6:68 doi:10.1186/1471-2202-6-68

Accepted: 29 November 2005

This article is available from: <http://www.biomedcentral.com/1471-2202/6/68>

© 2005 Ogier et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a multifunctional secreted protein with pleiotropic actions, including the inhibition of matrix metalloproteinases (MMPs), cell death/survival and growth promoting activities. After inflammatory challenge, the levels of TIMP-1 are highly and selectively upregulated in astrocytes among glial cells, but little is known about its role in these neural cells. We investigated the influence of TIMP-1 null mutation in the reactivity of cultured astrocytes to pro-inflammatory stimuli with TNF- $\alpha$  and anti-Fas antibody.


**Results:** When compared to WT, mutant astrocytes displayed an overall increased constitutive gelatinase expression and were less responsive to Fas-mediated upregulation of MMP-9, of monocyte chemoattractant protein-1 (MCP-1) and of intercellular cell adhesion molecule-1 (ICAM-1), all markers of astrocyte inflammatory response. In contrast, TNF- $\alpha$  treatment induced all these factors similarly regardless of the astrocyte genotype. The incorporation of <sup>3</sup>H-thymidin, a marker of cell proliferation, increased in wild-type (WT) astrocytes after treatment with anti-Fas antibody or recombinant TIMP-1 but not in mutant astrocytes. Finally, lymphocyte chemotaxis was differentially regulated by TNF- $\alpha$  in WT and TIMP-1 deficient astrocytes.

**Conclusion:** We provide evidence that the alteration of the MMP/TIMP balance in astrocytes influences their reactivity to pro-inflammatory stimuli and that Fas activation modulates the expression of members of the MMP/TIMP axis. We hypothesise that the Fas/FasL transduction pathway and the MMP/TIMP system interact in astrocytes to modulate their inflammatory response to environmental stimuli.

### Background


Injury in the central nervous system (CNS) is generally accompanied by an inflammatory reaction that involves

mainly microglia and astrocytes. The latter are the most abundant cells in the CNS and their contribution to the pathological outcome is still a matter of debate. In




**Figure 1**

Characterisation of astrocyte cultures. **A.** Epifluorescence photomicrographs showing combined labelling with anti-GFAP and anti-F4/80 antibodies, and nuclear intercalant Hoechst. Astrocyte culture were characterised as being greater than 95% pure by counting GFAP-positive cells and F4/80-positive cells (microglia) over the total number of cells stained by Hoechst. **B.** Expression of TIMP-1 in astrocytes was assessed by western blot; lane 1: mouse recombinant TIMP-1, lane 2: supernatant of WT astrocytes and lane 3: supernatant of KO astrocytes. **C.** Phase contrast photomicrographs of astrocyte cultures. No apparent morphological differences were seen between WT and KO astrocytes. **D.** Effect of treatments on cell viability. Only TNF- $\alpha$  treatment induced a mild cytotoxic effect on WT astrocytes. Values represent the mean  $\pm$  s.e.m. of at least three independent experiments. Statistical differences were determined by Student's *t*-test when comparing treatments to normalised values (\*  $p < 0.05$ ). Scale bar represents 50  $\mu$ m.




**Figure 2**

Expression of MMP-9 and MMP-2 in astrocytes. **A.** Gelatine zymograms from culture supernatants of WT and KO astrocytes in control condition (lane 1) or after treatment with TNF- $\alpha$  (lane 2) and anti-Fas antibody (lane 3). Quantitative expression of the 94 kDa (MMP-9) (**B**) and the 63 kDa form of MMP-2 (**C**). Constitutive levels of MMP-2 in KO were higher than in WT astrocytes. MMP-9 was up-regulated by TNF- $\alpha$  in both strains of astrocytes. Fas activation significantly induced MMP-9 expression in WT astrocytes but not in KO astrocytes. **D.** Total gelatinase expression detected in gel zymography. The total gelatinase expression was higher in KO astrocytes as compared to WT astrocytes. TNF- $\alpha$  and anti-Fas treatments increased total gelatinase expression only in WT astrocytes. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's *t*-test when comparing treatments to control cells within a given genotype (\* *p* < 0.05) or KO vs WT cells (● *p* < 0.05).



**Figure 3**


Expression of ICAM-1 in WT and KO astrocytes. **A.** Plots of flow cytometry after treatment with TNF- $\alpha$  or anti-Fas antibody. **B.** Quantification of ICAM-1 expression. ICAM-1 levels were up-regulated by TNF- $\alpha$  in astrocytes from WT and KO mice, whereas Fas activation increased ICAM-1 expression only in WT astrocytes. Values represent the mean  $\pm$  s.e.m. of at least three independent experiments. Statistical differences were determined by Student's *t*-test when comparing treatments to control cells (\*  $p < 0.05$ ).



**Figure 4**

Release of MCP-1 by WT and KO astrocytes was measured in supernatants by ELISA. MCP-1 release was up-regulated by TNF- $\alpha$  in astrocytes from WT and KO mice, whereas Fas activation increased MCP-1 release only in WT astrocytes. Values represent the mean  $\pm$  s.e.m. of at least three independent experiments. Statistical differences were determined by Student's *t*-test when comparing treatments to control cells (\*  $p < 0.05$ ).

response to injury, cytokines and chemokines trigger astrocyte proliferation and migration into the lesioned area where astrocytes contribute to the formation of the glial scar that inhibits axonal regeneration in the CNS [1]. Characteristic features of reactive astrocytes are morphological changes with cell body hypertrophy and increased expression of a number of proteins absent or weakly expressed in their resting state. Among these proteins, the MMPs and the TIMPs are highly upregulated in reactive astrocytes. TIMP-1 is a 31 kDa multifunctional secreted glycoprotein that possesses, in addition to its MMP inhibitor activity, growth promoting activities in a number of non neural cells [2-4]. We first demonstrated that TIMP-1 is massively and sequentially upregulated in cortical areas of rat brain after kainate-induced seizures, first in resistant neurons and subsequently in reactive astrocytes [5]. Selective TIMP-1 upregulation in astrocytes has also been reported after experimental autoimmune encephalomyelitis [6] or cerebral ischemia [7]. Interestingly, none of the aforementioned studies reported TIMP-1 expression in reactive microglial cells, highlighting the possibility of a specific role for TIMP-1 in astrocytes among glial cells. In cultured astrocytes, TIMP-1 is induced in response to a number of pro-inflammatory stimuli, including cytokines activated in the injured brain such as TNF- $\alpha$  or IL-1 $\beta$  [8-10], LPS [11] or after transient exposure to activated T lymphocytes [12]. Nevertheless, the effects of TIMP-1 in



**Figure 5**

Astrocyte proliferation was estimated by measuring <sup>3</sup>H-thymidine uptake, expressed in cpm. Note that constitutive uptake was higher in KO than in WT astrocytes. Both anti-Fas antibody and mrTIMP-1 increased proliferation of WT astrocytes but not of KO astrocytes. Values represent the mean  $\pm$  s.e.m. of at least three independent experiments. Statistical differences were determined by Student's *t* test when comparing treatments to control cells with the same genotype (\*  $p < 0.05$ ) or KO vs WT cells (●  $p < 0.05$ ).

astrocytes are still largely unknown. We thus investigated the influence of TIMP-1 null mutation [13] on the response of cultured astrocytes to two cytokines of the TNF superfamily known to be induced in similar physiological conditions than TIMP-1. Notably, TNF- $\alpha$  and the Fas/FasL system are known to be death molecules for different cell types [14-16], but act as pro-inflammatory agents in astrocytes [17-20] the latter being resistant to Fas mediated cytotoxic effects [21-23]. In addition, it is known MMPs may regulate the activity of the TNF and Fas systems by proteolytic cleavage of some of their members, including TNF- $\alpha$  [24], TNF-R [25], Fas-L [26,27] and Fas [28].

We provide evidence that the absence of TIMP-1 prevents the induction of MMP-9 and of inflammatory markers such as ICAM-1 or MCP-1 after Fas activation and that the mutant astrocytes proliferate less than the wild type in response to cytokines and to TIMP-1. TIMP-1 null mutation is also accompanied by an increased constitutive expression of gelatinases, mainly MMP-2. Altogether, these data indicate that the absence of TIMP-1 specifically attenuates the inflammatory response of astrocytes triggered by Fas but not by TNF- $\alpha$  and suggest that the MMP/

TIMP balance is an important determinant in the pro-inflammatory effects of some members of the TNF family.

## Results

### **Characterisation of astrocyte cultures**

Astrocyte cultures were characterised as being greater than 95% pure by counting GFAP positive cells over the total number of cells stained by Hoechts # 33258. Microglial cells stained with F4/80 constituted the majority of GFAP negative cells (Fig. 1A). We confirmed by western blot that WT astrocytes constitutively expressed TIMP-1 and that the protein was absent in astrocytes from KO mice (Fig. 1B). As shown in Fig. 1C, no morphological differences were observed between astrocytes from WT or KO mice and the density of confluent cells was equivalent. This observation was supported by the finding that the MTT levels were identical in untreated WT and TIMP-1 KO cultures. Parallel experiments using propidium iodide as a cell death marker showed no differences in the constitutive cell death of untreated astrocytes (2–3%) between WT and mutant mice (results not shown). We found a mild reduction (16%) in mitochondrial activity by the test MTT only in WT astrocytes treated by TNF- $\alpha$  and no effect after anti-Fas antibody exposure (Fig. 1D). We confirmed previous data [21–23] demonstrating the absence of anti-Fas toxicity in astrocytes.

### **TIMP-1 null mutation causes altered expression of MMP-2 and MMP-9**

It is widely accepted that astrocytes express soluble MMP-2 and 9 (also known as gelatinases A and B, respectively) and TIMP-1. As TIMP-1 is the preferential inhibitor of MMP-9 and a good inhibitor of MMP-2, we used gel zymography to evaluate whether TIMP-1 depletion would influence the expression of both proteinases in the supernatants of WT and KO cultures after treatments. In control cultures, gel zymography (Fig. 2A) revealed the expected MMP-9 94 kDa band, and a predominant band at 63 kDa and a weaker band at 68 kDa, both of them coherent with expected molecular weights for MMP-2 active forms. We also detected a conspicuous band at 130 kDa. The constitutive levels of MMP-2 were more than twice the levels of MMP-9 in both WT and mutant astrocytes. TIMP-1 null mutation had no significant effect on constitutive MMP-9 expression, but increased the baseline levels of MMP-2 by 60%, as compared with WT astrocytes (Fig. 2C). In the latter, TNF- $\alpha$  and Fas activation significantly increased MMP-9 expression (80% and 110%, respectively). In the KO astrocytes, MMP-9 levels were upregulated only after exposure to TNF- $\alpha$ , while Fas activation had no significant effect (Fig. 2B). Treatments did not change the levels of MMP-2 except the anti-Fas antibody which reduced MMP-2 levels in KO astrocytes. When considering the total pool of gelatinases detected by gel zymography, we found that its constitutive level was higher in the KO astrocytes and

increased with TNF- $\alpha$  and anti-Fas antibody in the WT astrocytes (Fig. 2D). Phenanthroline and BB-3103 abolished gelatinase activity, indicating that it was generated by metalloproteinases (not shown).

### **ICAM-1 and MCP-1 are differentially induced in WT and TIMP-1 KO astrocytes**


Astrocytes are the most abundant cells of the brain and express cytokines and adhesion molecules involved in different phases of neuroinflammation, including leukocyte recruitment in the CNS. Among these proteins, ICAM-1 and MCP-1 are strongly up-regulated during neuroinflammation, and preferentially in astrocytes [29–32]. Accordingly, both proteins are considered as markers of inflammatory response. In addition, the activities of ICAM-1 and MCP-1 are modulated by metalloproteinases [33,34]. For these reasons we examined whether the imbalance in the MMP/TIMP ratio observed in the mutant cultures would affect the levels of ICAM-1 and MCP-1 in astrocytes. As illustrated in figures 3 and 4, we found no differences in the constitutive expression of membrane bound ICAM-1 or release of MCP-1 between WT and KO cultures. However, exposure to TNF- $\alpha$  increased ICAM-1 levels in both WT and KO cultures (120% and 80%, respectively) (Fig. 3). An even higher upregulation of MCP-1 levels was observed after TNF- $\alpha$  in WT (215%) and KO (310%) (Fig. 4). In contrast, Fas activation upregulated ICAM-1 (70%) and MCP-1 (150%) levels only in WT mice, but not in TIMP-1 deficient astrocytes.

### **KO astrocytes proliferate less than WT astrocytes in response to TNF- $\alpha$ and anti-Fas**

Since cell proliferation is a hallmark of glial response to neuroinflammatory challenge, we measured the incorporation of  $^3\text{H}$ -thymidin, as an index of proliferation, into first passage synchronised astrocytes in response to cytokines and mrTIMP-1 (Fig. 5). We show that mrTIMP-1 induced the highest increase (200%) in proliferation of WT cells. Even though the levels of  $^3\text{H}$ -thymidin uptake in KO astrocytes treated with TIMP-1 were equivalent to those of WT astrocytes, statistical significance with respect to the untreated KO control was not reached, possibly because of a high level of constitutive  $^3\text{H}$ -thymidin incorporation in the mutant astrocytes. TNF- $\alpha$  did not significantly stimulate  $^3\text{H}$ -thymidin uptake in WT and KO astrocytes, unlike anti-Fas antibody that induced a significant 40% increase in WT but not in KO astrocytes.

### **Effect of WT and KO astrocytes on lymphocyte recruitment**

MCP-1 is one of the main chemokines involved in the chemoattraction of monocytes and lymphocytes under inflammatory conditions [35,36]. We investigated whether WT astrocytes showing a dramatic upregulation of MCP-1 after exposure to TNF- $\alpha$  or anti-Fas antibody,



**Figure 6**  
 The effect of astrocytes on lymphocyte migration was assessed using Transwell chambers and was expressed by the total number of migrated cells (A) and as an index of migration (B). Note that anti-Fas treatment alone without astrocytes in the lower compartment induced lymphocyte migration. Only KO astrocytes treated with TNF-α induced significant lymphocyte migration. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's *t*-test when comparing treatments to control cells (\* *p* < 0.05) or astrocytes vs no astrocyte (● *p* < 0.05).

would differentially affect lymphocyte migration as compared with KO astrocytes whose levels of MCP-1 were unaltered by anti-Fas antibody treatment. The data (Fig. 6) show that astrocytes alone increased by 300% the number of migrating lymphocytes regardless of the genotype. Moreover, in the absence of astrocytes, anti-Fas antibody alone was sufficient to significantly increase (200%) lymphocyte migration. However, the incubation of astrocytes with TNF-α increased the chemotaxis of lymphocytes, in particular in the KO astrocytes. In contrast, no effect of anti-Fas antibody was observed in WT or KO astrocytes as compared to their controls.

**Discussion**

The present report shows that TIMP-1 null mutation attenuates the inflammatory response of astrocytes to Fas activation. We show that TIMP-1 null mutation is associated with a higher constitutive MMP-2 expression, and that Fas activation fails to induce MMP-9, ICAM-1 and MCP-1 expression in KO astrocytes as it is the case in WT astrocytes. Moreover, KO astrocytes proliferate less than WT in response to anti-Fas and mrTIMP-1, whereas recruitment of lymphocytes is significantly induced only by TNF-α-treated astrocytes from KO mice.

The constitutive expression of gelatinases in general, and MMP-2 in particular, is higher in KO than in WT astrocytes, suggesting that in the absence of TIMP-1, the baseline regulation of one of its main targets is altered. The overall increase in gelatinase expression along with the absence of TIMP-1-mediated inhibition of MMPs in mutant astrocytes presumably increases MMP activity. As demonstrated previously in other cell types [37] and in brains from TIMP-1 KO mice [38], we assume that TIMP-1 deficiency is not compensated by the overexpression of other TIMPs, at least at the mRNA level. Our data showing a weak decrease of the mitochondrial activity after TNF-α exposure could be interpreted as a mild cytotoxic effect in agreement with studies reporting <20% astrocyte cell death after exposure to the cytokine [39]. We can not rule out the possibility that the absence of cell death under TNF treatment in KO astrocytes may be actually related to a relatively higher baseline proliferative potential in these cultures. We also show that astrocytes are resistant to Fas-mediated cell death in keeping with previous findings in human [21,22] and mouse astrocyte cultures [23]. Moreover, the TNF-α mediated induction of MMP-9 found in mouse astrocytes was equivalent to that reported in rat astrocytes [40]. However, this is the first report demonstrating that the activation of Fas stimulates MMP-9 release by astrocytes. Together, these data support the idea that the activation of receptors of the TNF superfamily triggers inflammatory rather than death signals in astrocytes, and that MMP-9 could act as an inflammatory factor downstream of Fas activation. It is likely that the induced expression of MMP-9 amplifies the inflammatory cascade initiated by cytokines through mechanisms involving the proteolytic activation of latent forms of cytokines. MMP-9 can proteolytically convert latent forms of TNF-α and IL-1β into active forms [24,41]. The presumably pro-inflammatory role of MMP-9 in astrocytes does not preclude its cytotoxic action demonstrated for cortical [42] and hippocampal [43] neurons in excitotoxic/inflammatory paradigms.

The most striking finding of the present study was the reduced response displayed by TIMP-1 deficient astrocytes to anti-Fas antibody, in clear contrast with the response of

their WT counterparts. Failure in inducing MMP-9, ICAM-1 and MCP-1 strongly suggests that the absence of TIMP-1 disturbs the Fas signal transduction pathway. TIMPs are considered as multifunctional proteins with anti-MMP, cell-death/survival, and growth promoting activities [44]. Some of the mechanisms underlying these actions are related with the ability of TIMPs to prevent proteolytic processing of membrane receptors, such as death receptors of the TNF superfamily. It has been suggested that the stabilisation of Fas by endogenous (TIMP-1 and TIMP-3) and synthetic MMP inhibitors is responsible for increased sensitivity to apoptosis of various cell types, including Dev neural precursors cells [45] or cancer cells [46]. Recently, MMP-7 has been identified as a sheddase of Fas that induces apoptosis resistance in tumour cells [47]. Considering that astrocytes express high constitutive levels of Fas [23] and that astrocytes deficient for TIMP-1 likely have an increased proteolytic activity, we hypothesise that constitutive cleavage of Fas may indeed reduce the levels of Fas at the membrane, and consequently hamper astrocyte reactivity to anti-Fas antibody treatment. MMP-2, whose levels are constitutively increased in TIMP-1 KO astrocytes, decreased however after anti-Fas treatment. It is tempting to speculate that elevated levels of MMP-2 contribute directly or indirectly to Fas cleavage in normal conditions. The exposure of cells to a Fas-L-like factor would favour the downregulation of MMP-2 in an attempt to re-establish the levels of the receptor. Nevertheless, the role of MMP-2 as a Fas sheddase has not been demonstrated yet.

Together, these data bring support to the hypothesis that TIMP-1 exerts a pro-inflammatory effect by facilitating astrocyte reactivity through the regulation of the MMP/TIMP balance. Astrocyte proliferation is a hallmark of reactivity in inflammatory settings. For the first time, we demonstrate that TIMP-1 induces astrocyte proliferation and this effect is stronger than the effects mediated by TNF- $\alpha$  or anti-Fas antibody. Our data support the idea that TIMP-1 exerts a control on cell growth, as previously suggested by other authors in different cell types [48,4]. Moreover, it has been shown that TIMP-1 accumulates in the nucleus of some cell types [49] and it has been suggested that it could regulate the cell cycle via a MMP-independent mechanism. This idea is reinforced by the finding in our laboratory that mrTIMP-1 increases by 2-fold the number of astrocytes in a mixed neuronal-astrocyte culture, and that this effect is not mimicked by broad spectrum MMP inhibitors (unpublished results). The baseline level of  $^3\text{H}$ -thymidin uptake in KO astrocytes was higher than in the WT. Perhaps, for this reason, a pro-inflammatory stimulus with cytokines or TIMP-1 did not induce further significant increases in KO astrocyte proliferation. It is possible that a low constitutive expression of TIMP-1 maintains astrocytes in a resting "low proliferative" state

that reacts promptly to a pro-inflammatory stimulus. On the contrary, the chronic absence of TIMP-1 may cause a state of permanent mild "reactivity" or "inflammatory status" that increases the response threshold for new exogenous pro-inflammatory stimuli. From the above, it follows that TIMP-1 might actually act as a homeostatic factor for astrocytes in the resting state, and as a pro-inflammatory factor in stressful conditions, notably in seizing and ischemic brains, where early and massive induction of TIMP-1 in neurons [5,7] precede astrocyte reactivity. Pro-inflammatory effects of TIMP-1 have also been suggested in *in vivo* models of rheumatoid arthritis [50].

We expected that mutant astrocytes resistant to Fas-mediated induction of MCP-1 would attract lymphocytes less efficiently than WT astrocytes displaying a strong upregulation of MCP-1 in the same treatment conditions. The fact that untreated astrocytes did increase by 300% the number of migrating lymphocytes clearly indicates that these glial cells have a strong chemoattractant capacity in culture conditions, perhaps in part because of their constitutive MCP-1 release. Moreover, the finding that anti-Fas antibody alone caused a 200% increase in lymphocyte migration reveals also a potent chemotactic effect of FasL, independently of its cellular source, in clear contrast with the absence of chemotactic effects of TNF- $\alpha$  alone. These data are coherent with previous reports demonstrating that soluble FasL is chemotactic for neutrophils and that an anti-Fas antibody mimics this effect [51]. In addition, it has been shown that Fas activation stimulates motility in the absence of cytotoxicity [52]. In our experimental model, it is possible that the threshold of stimulation necessary for Fas/astrocyte-mediated lymphocyte migration is already achieved by the individual components of the tandem.

The strong chemoattractant effect of TIMP-1 deficient astrocytes when exposed to TNF- $\alpha$ , cannot be interpreted on the basis of the MCP-1 release, since the latter was equivalent in both WT and TIMP-1 deficient cells. This finding suggests that MCP-1 alone is not sufficient to critically influence the chemoattraction of lymphocytes. The activity of MCPs is regulated by MMP-mediated proteolytic processing, resulting in new bioactive truncated proteins with antagonist effects on leukocyte migration. In this scenario, MMPs would indirectly act as anti-inflammatory agents [34]. However, we cannot speculate on a possible interaction between gelatinases (MMP-2 and MMP-9) and MCP-1 since the latter has been reported to be specifically cleaved by MMP-1 and MMP-3 [34]. An alternative way of interpreting the increased lymphocyte migration in the TIMP-1 deficient astrocytes exposed to TNF- $\alpha$ , refers to the possible regulation of ICAM-1 by gelatinases at the surface of astrocytes; MMPs cleave mem-



brane-bound ICAM-1 in astrocytes [53], and MMP-9 appears to be the key enzyme processing ICAM-1 in tumour cells [54]. Soluble ICAM-1 (sICAM-1) generated by this cleavage has been reported to induce macrophage inflammatory protein-2 (MIP-2) in mouse astrocytes and subsequently stimulate leucocytes migration [55]. A lower TIMP-1 inhibitory capacity in the mutant astrocytes, along with an increased gelatinase activity, would favour sICAM-1 proteolytic generation and possibly lymphocyte migration after TNF- $\alpha$  treatment. This idea is coherent with the overall lower ICAM-1 levels found in the TIMP-1 KO mice.

## Conclusion

In summary, the present data provide evidence linking the MMP/TIMP balance to the reactive response of astrocytes following pro-inflammatory stimuli. The control of astrocyte reactivity by the MMP/TIMP axis affects in a particular way the Fas/FasL pathway, and suggests that in astrocytes, the outcome of the neuroinflammatory status in pathological situations may involve the mutual regulation of these two molecular systems. We can not exclude that other MMP substrates (ICAM, MCPs) are also affected by changes in the proteolytic balance. We are just starting to unveil the importance that the proteolytic modification of bioactive factors may have in the control of cell behaviour and intercellular communication. The study of the MMP/TIMP roles in neural cells and of the mechanisms whereby these proteinases and inhibitors exert the control of cell behaviour is a challenging question that needs further investigation.

## Methods

### Animals

All experimental procedures were performed in compliance with our institutional guidelines after obtaining the authorisation of the Laboratory Animal Committee of the Medical Faculty.

TIMP-1 deficient mice (Sv-129) were generated by homologous recombination and functional TIMP-1 protein was detected in WT cells, but not in co-isogenic cell lines carrying the mutation in *Timp1* [13]. Genetically modified (KO) and WT mice have an identical genetic background. Genomic DNA was extracted from the tail tips of mice to determine their genotype by PCR.

### Astrocyte cultures

Astrocytes were obtained from the brains of 2-day-old mice. After removal of the meninges, the brains were dissociated into a single-cell suspension by trypsinisation and mechanical disruption. The cells were seeded on poly-L-lysine (Sigma St Louis, MO, USA) coated culture plates at the density of  $4 \times 10^4$  cells per  $\text{cm}^2$  and grown at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  humidified atmosphere in Dulbecco's

Modified Eagle Medium (DMEM) containing 10% foetal calf serum, 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100  $\mu\text{g}/\text{ml}$ ) (all from InVitrogen, Carlsbad, CA, USA). The medium was replaced every 3 days. After 8–10 days *in vitro*, the medium was changed for 24 h into serum free medium containing DMEM, 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100  $\mu\text{g}/\text{ml}$ ), 5  $\mu\text{g}/\text{ml}$  insulin (Sigma,) and 0,05% bovine serum albumin (BSA – InVitrogen). Cells were then treated for 24 h with 10 ng/ml TNF- $\alpha$  (R&D Systems, Minneapolis, MN, USA) and 0.5  $\mu\text{g}/\text{ml}$  hamster anti-mouse Fas antibody (Clone Jo2, BD Pharmingen, San Jose, CA, USA) which mimics the effects of FasL, activates Fas and stimulates pro-inflammatory responses from astrocytes [23].

### Western blot

Protein concentration of culture supernatants was normalised using the Lowry method (DC-Protein assay, Bio-Rad, Hercules, CA, USA). Using a Bio-Rad MiniBlot system, equal amounts of protein were subjected to 8.5% sodium dodecyl sulphate – polyacrylamide gels electrophoresis (SDS-PAGE), under reducing and denaturing conditions, and then transferred to PVDF immunoblotting membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). TIMP-1 was detected by a goat anti-mouse TIMP-1 antibody (R&D Systems), followed by biotinylated anti-goat IgG and streptavidin-peroxidase (both from Jackson ImmunoResearch, West Grove, PA, USA), and then visualised by chemiluminescence reaction using the ECL system (Amersham). Glycosylated mouse recombinant (mr) TIMP-1 (R&D Systems) was used as a control in each gel.

### Astrocyte and microglia staining

In order to characterise the cell type composition of our cultures we used glial fibrillary acidic protein (GFAP) as an astrocytic marker and F4/80 as a microglial marker. Briefly, cells were preincubated with 0.1% triton X-100 and 5% normal goat serum (NGS) for 30 min, incubated with rabbit anti-cow GFAP (DAKO, Glostrup, Denmark) (1/500) and rat anti-mouse F4/80 (Serotec, Kidlington, Oxford, UK) (1/500) antibodies diluted in PBS containing 0.1% triton X-100 and 5% serum for 1 h. Cells were then rinsed in PBS, incubated for 1 h with Alexa Fluor<sup>®</sup> 594 anti-rabbit and Alexa Fluor<sup>®</sup> 488 anti-rat antibodies respectively (Molecular Probes, Eugene, OR, USA), rinsed in PBS, and the DNA intercalant Hoechts #33258 (Molecular Probes) was added during 5 min to label cell nuclei. Cells were then mounted in fluorescent mounting medium (DAKO), observed under a Nikon E800 upright microscope (Nikon Champigny-sur-Marne, France) equipped with epifluorescence, TRITC, FITC and DAPI filters, DXM 1200 camera and the LUCIA image analysis software.

### **3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay**

In order to test a possible cytotoxic effect of treatments, TNF- $\alpha$  and anti-Fas antibody were incubated for 24 h and cell death measured by the MTT (Sigma) assay that detects mitochondrial activity in living cells [56]. Results are expressed as the arbitrary units of optical density. The means  $\pm$  S.E.M. were obtained from triplicates within a single experiment and at least three independent experiments.

### **Gel zymography**

Equal amounts of protein were subjected to 8.5% SDS-PAGE containing 0.5% gelatine (Sigma) in non-denaturing, non-reducing conditions. Gels were washed twice for 15 min in 2.5% Triton X-100 to remove SDS, and incubated at 37°C for 22 h in 100 mM Tris pH 7.4 and 15 mM CaCl<sub>2</sub>. Gels were then stained with 0.1% Coomassie blue R-250 (Bio-Rad) for 20 min and destained in 10% acetic acid until clear bands of gelatinolysis appeared on a dark background. Bacterial collagenase (10<sup>-2</sup> U/ml, Sigma) was loaded in each gel as a control and used for normalisation. Gels were scanned and bands were quantified using GeneTools software. Each test was performed in triplicate within single experiments and means  $\pm$  S.E.M. were obtained from at least three independent experiments. Some zymogram gels were incubated with 1 mM 1,10-phenanthroline (Sigma) or BB-3103, two broad spectrum inhibitors of metalloproteinases.

### **Flow cytometry**

Astrocyte cultures were incubated on ice for 15 min with the rat anti-mouse ICAM-1 antibody purified from the supernatants of YN1 hybridoma cells (R&D Systems). After washes, cells were treated with FITC-labelled goat anti-rat IgG (Jackson ImmunoResearch) for 15 min in ice. Cells were washed, centrifuged and resuspended in PBS and 2% paraformaldehyde. A control without anti-ICAM-1 antibody served as blank to normalise the mean of fluorescence. FACS analysis was performed on a FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA) using Cellquest Software (Becton Dickinson). The number of positive cells in each assay was standardised to 5000. Results were expressed in arbitrary units corresponding to the mean of fluorescence, and were obtained from at least three independent experiments.

### **Enzyme linked immuno-adsorbent assay for MCP-1**

MCP-1 expression in astrocyte supernatants was measured using an ELISA kit (BD Pharmingen) according to the manufacturer's instructions. Equal amounts of protein were added onto anti-mouse MCP-1 antibody-coated wells, detected by horseradish peroxidase-conjugated anti-mouse MCP-1 antibody and revealed with o-phenylenediamine. Recombinant mouse MCP-1 was used as

control to determine the concentration of MCP-1 in the sample. Each test was performed in triplicate within single experiments and means  $\pm$  S.E.M. were obtained from at least three independent experiments.

### **Proliferation assay by <sup>3</sup>H-thymidin incorporation**

After 8–10 days *in vitro*, astrocytes were trypsinised and reseeded in serum containing medium in 96-well flat-bottom plates, at the density of 10<sup>4</sup> cells per well. Twenty four hours after, the culture medium was replaced with serum-free medium for 24 h and cells were then treated with TNF- $\alpha$ , anti-Fas antibody or mrTIMP-1 in triplicate. Two days later, 1  $\mu$ Ci of <sup>3</sup>H thymidin (Amersham Pharmacia Biotech) was added in each well. After 18 h, cells were harvested on filter mats, dried and counted using 1600TR liquid scintillation analyser (Pachard Instruments, Meriden, CT, USA). The results were expressed as total cpm. Each test was performed in triplicate within single experiments and means  $\pm$  S.E.M. were obtained from at least three independent experiments.

### **Lymphocyte recruitment in transwell chambers**

We used a transwell system in order to evaluate the influence of astrocytes treated with TNF- $\alpha$  and anti-Fas antibody on lymphocyte migration. Lymphocytes were obtained from spleen, cultured at 4  $\times$  10<sup>4</sup> cells per cm<sup>2</sup> and activated with recombinant IL-2 (InVitrogen) and with the supernatant of splenic cells stimulated with concanavalin A (Sigma). Astrocytes were seeded in the lower part of the well, as described above, and treated for 24 h with TNF- $\alpha$  or anti-Fas antibody in a serum free medium. Lymphocytes were labelled with 10  $\mu$ M CFSE (5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (5(6)-CFDA, SE; CFSE – Molecular Probes) by a 15 min incubation. Lymphocytes (1.5  $\times$  10<sup>4</sup> per well) were then seeded on the upper part of 3  $\mu$ m pore clear polycarbonate transwells (Costar, Cambridge, MA, USA) and allowed to migrate for 7 hours. The filters were then removed and photomicrographs of migrated lymphocytes in the lower well were taken using a Nikon TE300 inverted microscope equipped a FITC filter, and images were analysed using a DXM 1200 camera and the LUCIA image analysis software (Nikon). Wells without astrocytes in the lower part or astrocytes without treatment were used as controls. The number of labelled lymphocytes in the lower compartment was quantified using GenTools software (Syngene). Tests were performed in triplicate within single experiments and means  $\pm$  S.E.M. were obtained from three independent experiments.

### **List of abbreviations**

CNS, central nervous system; ICAM-1, intercellular adhesion molecule-1; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of MMP; TNF, Tumour Necrosis Factor.

## Authors' contributions

CO performed most of the assays and co-wrote the manuscript.

RC participated to the lymphocyte recruitment assay.

JB made substantial contributions to conception and design of experiments.

PS provided the transgenic mice.

MK contributed to design the project and revised the manuscript for important intellectual content.

SR supervised the project and wrote the manuscript.

All authors read and approved the final manuscript and its submission to BMC Neuroscience.

## Acknowledgements

This work was supported by funding from CNRS, from the Faculty of Medicine of Marseille (BQR) and from the Association pour la Recherche sur la Sclérose en Plaques (ARSEP). C.O. was granted a fellowship from "La Ligue Contre le Cancer". BB-3103 was provided by British Biotech Pharmaceuticals.

## References

- Fawcett JW, Asher RA: **The glial scar and central nervous system repair.** *Brain Res Bull* 1999, **49**:377-391.
- Gasson JC, Golde DW, Kaufman SE, Westbrook CA, Hewick RM, Kaufman RJ, Wong GG, Temple PA, Leary AC, Brown EL, Orr EC, Clark SC: **Molecular characterization and expression of the gene encoding human erythroid-potentiating activity.** *Nature* 1985, **315**:768-771.
- Bertaux B, Hornebeck W, Eisen AZ, Dubertret L: **Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases.** *J Invest Dermatol* 1991, **97**:679-685.
- Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K: **Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum.** *FEBS Lett* 1992, **298**:29-32.
- Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, Khrestchatsky M: **Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response.** *J Neurosci* 1997, **17**:4223-4235.
- Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL: **Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states.** *Am J Pathol* 1998, **152**:729-741.
- Rivera S, Ogier C, Jourquin J, Timsit S, Szklarczyk AW, Miller K, Gearing AJ, Kaczmarek L, Khrestchatsky M: **Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia.** *Eur J Neurosci* 2002, **15**:19-32.
- Gottschall PE, Deb S: **Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons.** *Neuroimmunomodulation* 1996, **3**:69-75.
- Bugno M, Witek B, Bereta J, Bereta M, Edwards DR, Kordula T: **Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines.** *FEBS Lett* 1999, **448**:9-14.
- Suryadevara R, Holter S, Borgmann K, Persidsky R, Labenz-Zink C, Persidsky Y, Gendelman HE, Wu L, Ghorpade A: **Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia.** *Glia* 2003, **44**:47-56.
- Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, Cheong JH, Ryu JH, Ko KH: **Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2).** *Glia* 2003, **41**:15-24.
- Giraudon P, Szymocha R, Buart S, Bernard A, Cartier L, Belin MF, Akaoka H: **T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-1-induced neurological disease.** *J Immunol* 2000, **164**:2718-2727.
- Soloway PD, Alexander CM, Werb Z, Jaenisch R: **Targeted mutagenesis of TIMP-1 reveals that lung tumor invasion is influenced by TIMP-1 genotype of the tumor but not by that of the host.** *Oncogene* 1996, **13**:2307-2314.
- Nagata S: **Fas ligand-induced apoptosis.** *Annu Rev Genet* 1999, **33**:29-55.
- Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP: **Tumor necrosis factor receptor and Fas signaling mechanisms.** *Annu Rev Immunol* 1999, **17**:331-367.
- Beyaert R, Van Loo G, Heyninck K, Vandenaebelle P: **Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas.** *Int Rev Cytol* 2002, **214**:225-272.
- Wosik K, Becher B, Ezman A, Nalbantoglu J, Antel JP: **Caspase 8 expression and signaling in Fas injury-resistant human fetal astrocytes.** *Glia* 2001, **33**:217-224.
- Magnusson C, Vaux DL: **Signalling by CD95 and TNF receptors: not only life and death.** *Immunol Cell Biol* 1999, **77**:41-46.
- Becher B, Barker PA, Owens T, Antel JP: **CD95-CD95L: can the brain learn from the immune system?** *Trends Neurosci* 1998, **21**:114-117.
- Saas P, Walker PR, Quiquerez AL, Chalmers DE, Arrighi JF, Lienard A, Boucraut J, Dietrich PY: **A self-defence mechanism of astrocytes against Fas-mediated death involving interleukin-8 and CXCR2.** *Neuroreport* 2002, **13**:1921-1924.
- Becher B, D'Souza SD, Troutt AB, Antel JP: **Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity.** *Neuroscience* 1998, **84**:627-634.
- Saas P, Boucraut J, Quiquerez AL, Schnuriger V, Perrin G, Desplat-Jego S, Bernard D, Walker PR, Dietrich PY: **CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation?** *J Immunol* 1999, **162**:2326-2333.
- Lee SJ, Zhou T, Choi C, Wang Z, Benveniste EN: **Differential regulation and function of Fas expression on glial cells.** *J Immunol* 2000, **164**:1277-1285.
- Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al.: **Processing of tumour necrosis factor-alpha precursor by metalloproteinases.** *Nature* 1994, **370**:555-557.
- Wetzel M, Rosenberg GA, Cunningham LA: **Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis.** *Eur J Neurosci* 2003, **18**:1050-1060.
- Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: **Metalloproteinase-mediated release of human Fas ligand.** *J Exp Med* 1995, **182**:1777-1783.
- Tanaka M, Itai T, Adachi M, Nagata S: **Downregulation of Fas ligand by shedding.** *Nat Med* 1998, **4**:31-36.
- Xia M, Xu C, Ji S, Xue S: **Shedding of Fas ectodomain that affects apoptosis of hepatocytes occurring in regenerative liver.** *J Gastroenterol* 2002, **37**:1042-1047.
- Lee SJ, Benveniste EN: **Adhesion molecule expression and regulation on cells of the central nervous system.** *J Neuroimmunol* 1999, **98**:77-88.
- Huang D, Han Y, Rani MR, Glabinski A, Trebst C, Sorensen T, Tani M, Wang J, Chien P, O'Bryan S, Bielecki B, Zhou ZL, Majumder S, Ransohoff RM: **Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation.** *Immunol Rev* 2000, **177**:52-67.
- Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY: **TWEAK stimulation of astrocytes and the proinflammatory consequences.** *Glia* 2000, **32**:102-107.

32. Dong Y, Benveniste EN: **Immune function of astrocytes.** *Glia* 2001, **36**:180-190.
33. Lyons PD, Benveniste EN: **Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease.** *Glia* 1998, **22**:103-112.
34. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM: **Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.** *Blood* 2002, **100**:1160-1167.
35. Penido C, Vieira-de-Abreu A, Bozza MT, Castro-Faria-Neto HC, Bozza PT: **Role of monocyte chemotactic protein-1/CC chemokine ligand 2 on gamma delta T lymphocyte trafficking during inflammation induced by lipopolysaccharide or Mycobacterium bovis bacille Calmette-Guerin.** *J Immunol* 2003, **171**:6788-6794.
36. Babcock AA, Kuziel WA, Rivest S, Owens T: **Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS.** *J Neurosci* 2003, **23**:7922-7930.
37. Nothnick WB, Soloway PD, Curry TEJ: **Pattern of messenger ribonucleic acid expression of tissue inhibitors of metalloproteinases (TIMPs) during testicular maturation in male mice lacking a functional TIMP-1 gene.** *Biol Reprod* 1998, **59**:364-370.
38. Jourquin J, Tremblay E, Bernard A, Charton G, Chaillan FA, Marchetti E, Roman FS, Soloway PD, Dive V, Yiotakis A, Khrestchatsky M, Rivera S: **Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Modulates Neuronal Death, Axonal Plasticity, and Learning and Memory.** *Eur J Neurosci* **22**:2569-2578.
39. Kitsberg D, Formstecher E, Fauquet M, Kubes M, Cordier J, Canton B, Pan G, Rolli M, Glowinski J, Chneiweiss H: **Knock-out of the neural death effector domain protein PEA-15 demonstrates that its expression protects astrocytes from TNFalpha-induced apoptosis.** *J Neurosci* 1999, **19**:8244-8251.
40. Gottschall PE, Yu X: **Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes.** *J Neurochem* 1995, **64**:1513-1520.
41. Schonbeck U, Mach F, Libby P: **Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing.** *J Immunol* 1998, **161**:3340-3346.
42. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA: **S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death.** *Science* 2002, **297**:1186-1190.
43. Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatsky M, Rivera S: **Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate.** *Eur J Neurosci* 2003, **18**:1507-1517.
44. Mannello F, Gazzanelli G: **Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications.** *Apoptosis* 2001, **6**:479-482.
45. Giraudon P, Malcus C, Chalon A, Vincent P, Khuth S, Bernard A, Belin MF: **[Astrocytes, cells involved in neuro-immune interactions in the central nervous system].** *J Soc Biol* 2003, **197**:103-112.
46. Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE, Kahari VM: **Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors.** *Oncogene* 2003, **22**:2121-2134.
47. Strand S, Vollmer P, van den Abeelen L, Gottfried D, Alla V, Heid H, Kuball J, Theobald M, Galle PR, Strand D: **Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells.** *Oncogene* 2004, **23**:3732-3736.
48. Gasson JC, Golde DW, Kaufman SE, Westbrook CA, Hewick RM, Kaufman RJ, Wong GG, Temple PA, Leary AC, Brown EL, et al.: **Molecular characterization and expression of the gene encoding human erythroid-potentiating activity.** *Nature* 1995, **315**:768-771.
49. Zhao WQ, Li H, Yamashita K, Guo XK, Hoshino T, Yoshida S, Shinya T, Hayakawa T: **Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts.** *J Cell Sci* 1998, **111 (Pt 9)**:1147-1153.
50. Apparailly F, Noel D, Millet V, Baker AH, Lisignoli G, Jacquet C, Kaiser MJ, Sany J, Jorgensen C: **Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis.** *Arthritis Rheum* 2001, **44**:1444-1454.
51. Seino K, Iwabuchi K, Kayagaki N, Miyata R, Nagaoka I, Matsuzawa A, Fukao K, Yagita H, Okumura K: **Chemotactic activity of soluble Fas ligand against phagocytes.** *J Immunol* 1998, **161**:4484-4488.
52. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME: **CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.** *Embo J* 2004, **23**:3175-3185.
53. Lyons PD, Benveniste EN: **Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease.** *Glia* 1998, **22**:103-112.
54. Fiore E, Fusco C, Romero P, Stamenkovic I: **Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity.** *Oncogene* 2002, **21**:5213-5223.
55. Otto VI, Gloor SM, Frenzels S, Gilli U, Ammann E, Hein AE, Folkers G, Trentz O, Kossmann T, Morganti-Kossmann MC: **The production of macrophage inflammatory protein-2 induced by soluble intercellular adhesion molecule-1 in mouse astrocytes is mediated by src tyrosine kinases and p42/44 mitogen-activated protein kinase.** *J Neurochem* 2002, **80**:824-834.
56. Mosmann T: **Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.** *J Immunol Methods* 1983, **65**:55-63.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

